Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of FC?R1? gene expression and/or or activity, and/or modulate a FC?R1? gene expression pathway. Specifically, the invention relates to doublestranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against FC?R1? gene expression.
Type:
Application
Filed:
March 25, 2010
Publication date:
January 5, 2012
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Vasant Jadhav, Victoria Pickering, Walter Strapps
Abstract: The present invention relates to thiophene derivatives, to processes and intermediates for the preparation thereof, to the use thereof for optical, electro-optical and electronic purposes, in particular in liquid-crystal (LC) media and LC displays, and to LC media and LC displays comprising same.
Type:
Application
Filed:
February 3, 2010
Publication date:
January 5, 2012
Applicant:
MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
Inventors:
Axel Jansen, Detlef Pauluth, Harald Hirschmann, Markus Czanta
Abstract: The present invention relates to an electronic device, in particular an organic electroluminescent device, which comprises metal complexes containing azaborole ligands. The invention also relates to the metal complexes themselves, to the use thereof in an organic electronic device, and to a process for the preparation thereof. Finally, the invention is directed to the ligands and to the use of the ligands for the preparation of the metal complexes according to the invention.
Type:
Application
Filed:
February 3, 2010
Publication date:
January 5, 2012
Applicant:
Merck Patent GmbH
Inventors:
Philipp Stoessel, Holger Heil, Dominik Joosten, Christof Pflumm, Anja Gerhard
Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of ICAM-1 gene expression and/or activity, and/or modulate a ICAM-1 gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against ICAM-1 gene expression.
Type:
Application
Filed:
March 25, 2010
Publication date:
January 5, 2012
Applicant:
Merck Sharp & Dohme Corp,
Inventors:
Victoria Pickering, Jyoti K. Shah, Walter Strapps
Abstract: The present invention relates to the use of SNPs in predicting susceptibility and/or severity of Multiple Sclerosis in an individual. The SNPs are located in the introns of the glycosylation enzymes MGAT5 and XYLT1, 3? of HIF1AN, within introns of MEGF11. FGF14, PDE9A and CDH13 and within desert regions of 4q34 and 17p13.
Type:
Application
Filed:
March 25, 2010
Publication date:
January 5, 2012
Applicant:
MERCK SERONO SA
Inventors:
Hadi Abderrahim, Jérôme Wojcik, Federica Esposito, Virginie Debailleul
Abstract: The present invention relates firstly to HF/fluoride-free etching and doping media which are suitable both for the etching of silicon dioxide layers and also for the doping of underlying silicon layers. The present invention also relates secondly to a process in which these media are employed.
Abstract: The invention relates to phosphors having a garnet structure of the formula I (Ya,Gdb,Luc,Sed,Sme,Tbf,Prg,Thh,Iri,Sbj,Bik)3-x(All,Gam)5O12:Cex??(I) where a+b+c+d+e+f+g+h+i+j+k=1 l+m=1 and x=0.005 to 0.1, and to a process for the preparation of these phosphors, and to the use thereof as conversion phosphors for conversion of the blue or near-UV emission from an LED.
Type:
Grant
Filed:
February 13, 2008
Date of Patent:
January 3, 2012
Assignee:
Merck Patent Gesellschaft mit beschrankter Haftung
Inventors:
Holger Winkler, Tim Vosgroene, Thomas Juestel, Stephanie Moeller
Abstract: The invention relates to a method of genotyping and for predicting the susceptibility for SLE and/or MS by using SNPs related to BANK1 alone or in combination with at least one other SNP.
Type:
Application
Filed:
March 1, 2010
Publication date:
December 29, 2011
Applicant:
MERCK SERONO S.A.
Inventors:
Jérôme Wojcik, Marta Alarcôn-Riquelme, Casimiro Castillejo-López
Abstract: The present invention is related to pyrazine derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.
Type:
Application
Filed:
August 31, 2011
Publication date:
December 29, 2011
Applicant:
MERCK SERONO SA
Inventors:
PASCALE GAILLARD, Anna Quattropani, Vincent Pomel, Thomas Rueckle, Jasna Klicic, Dennis Church
Abstract: The present invention relates to metal complexes of the general formulae I to V, in particular as emitter molecules in organic electronic devices, to ligands of the general formulae Ia to Va, and to the use thereof for the preparation of metal complexes, to a layer and an electronic device which comprise the compounds according to the invention, and to a process for the preparation of the compounds according to the invention.
Type:
Application
Filed:
February 15, 2010
Publication date:
December 29, 2011
Applicant:
MERCK PATENT GMBH
Inventors:
Philipp Stoessel, Holger Heil, Dominik Joosten, Christof Pflumm, Anja Gerhard
Abstract: The present invention relates to a liquid-crystalline medium having high twist, to the use thereof for electro-optical purposes, and to displays containing this medium.
Type:
Application
Filed:
June 23, 2011
Publication date:
December 29, 2011
Applicant:
MERCK PATENT GmbH mit beschraenkter Haftung
Abstract: The invention relates to compounds of the formula (I), in which X, -Q1-Q2- and RF have the meaning indicated in Claim 1, as ionic liquids, and to a process for the preparation thereof.
Type:
Grant
Filed:
January 3, 2005
Date of Patent:
December 27, 2011
Assignee:
Merck Patent GmbH
Inventors:
Nikolai (Mykola) Ignatyev, Urs Welz-Biermann, German Bissky, Helge Willner, Andriy Kucheryna
Abstract: The present invention is related to pyrazine derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.
Type:
Application
Filed:
August 31, 2011
Publication date:
December 22, 2011
Applicant:
MERCK SERONO SA
Inventors:
Pascale Gaillard, Anna Quattropani, Vincent Pomel, Thomas Rueckle, Jasna Klicic, Dennis Church
Abstract: Disclosed are C-ring modified tricyclic benzonaphthiridinone compounds and analogs thereof, pharmaceutical compositions comprising such compounds and processes for preparing the same. The compounds are useful in the treatment of diseases amenable to protein kinase signal transduction inhibition, regulation and/or modulation.
Type:
Application
Filed:
December 2, 2009
Publication date:
December 22, 2011
Applicant:
MERCK PATENT GMBH
Inventors:
Yufang Xiao, Bayard R. Huck, Amanda E. Sutton, Thomas E. Richardson, Srinivasa R. Karra
Abstract: This invention relates to coloured polymer particles preferably with surface functionality for charge retention, a process for their preparation, the use of these particles for the preparation of an electrophoretic device, and to colour electrophoretic displays comprising such particles.
Type:
Application
Filed:
January 29, 2010
Publication date:
December 22, 2011
Applicant:
MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
Inventors:
Louise Diane Farrand, Ashley Nathan Smith, Mark James, Jonathan Henry Wilson, Daniel Walker
Abstract: The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.
Abstract: The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections.
Type:
Grant
Filed:
May 20, 2011
Date of Patent:
December 20, 2011
Assignees:
Insituto di Ricerche di Biologia Molecolare P. Angeletti SpA, Merck Sharp & Dohme Corp.
Inventors:
Steven Harper, Vincenzo Summa, Nigel J. Liverton, John A. McCauley
Abstract: Disclosed are prodrug compounds of formula (I) (wherein variables R1 and R2 are as described herein) which are analogues of an antagonist of CGRP receptors and which are useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
Type:
Grant
Filed:
February 4, 2009
Date of Patent:
December 20, 2011
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Ian M. Bell, Steven N. Gallicchio, Valentino J. Stella
Abstract: The present invention relates to pyridine substituted ethanol compounds and derivatives thereof having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
Type:
Grant
Filed:
January 29, 2007
Date of Patent:
December 20, 2011
Assignee:
Merck Sharp & Dohme
Inventors:
B. Wesley Trotter, Kausik K. Nanda, Nathan R. Kett
Abstract: The present invention provides oxadiazole pyridine derivatives of Formula (I), their use as medicaments and their use for treating multiple sclerosis and other diseases.
Type:
Application
Filed:
March 2, 2010
Publication date:
December 15, 2011
Applicant:
Merck Serono SA
Inventors:
Anna Quattropani, Patrick Gerber, Jerome Dorbais